Latest filing published 19 Oct 2026 for Iambic Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Evan Lockwood Rachlin: trading record in brief
Evan Lockwood Rachlin discloses dealings in Iambic Therapeutics, Inc. to SEC (Form 4). The record holds 4 filings, all for trades on 16 October 2026.
On the market, this insider has only ever bought: 1 purchase, €10.3M in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
On 19 October 2026 came the latest disclosure, a transaction in Iambic Therapeutics, Inc. The last purchase on record was published on 19 October 2026, which is 22 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Evan Lockwood Rachlin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,458,736 sharesCommon StockSEC:0002151678-26-000007:0
- 410,762 sharesCommon StockSEC:0002151678-26-000007:1
- 718,750 shares@ US$16.00Common StockSEC:0002151678-26-000007:2Canonical exit: 14 Jan 2027 (T+90)
- 57,754 sharesCommon StockSEC:0002151678-26-000007:3
4 of 4 declarations